Association between high-flow nasal oxygen and in-hospital mortality: evidence from children with asthma
Published
October 21, 2025
Paper ID
PAP-000100
Status
Published
DOI
10.65712/tmj.test000358
Advance Services
Abstract
Background: Guidelines make only a weak recommendation on high-flow nasal oxygen. Methods: The primary outcome was in-hospital mortality, assessed blind to allocation. Results: 1858 participants were included (median age 47 years). in-hospital mortality occurred in 20% of the intervention group versus 32% of controls. Conclusion: Future work should test high-flow nasal oxygen in a pragmatic multicentre trial.
References
1. Volkov W, Zhang S, et al. Delayed cord clamping and glycaemic control. Lancet. 2021;259(12):509-1093.
2. Okafor N, Mueller D, et al. SGLT2 inhibitors and 30-day readmission. Crit Care Med. 2016;65(12):804-1209.
3. Moreau H, Haddad B, et al. Machine-learning triage and acute kidney injury. Crit Care Med. 2009;360(1):345-1028.
4. Silva A, Schmidt Z, et al. Pharmacist-led medication review and medication adherence. BMJ. 2012;90(1):123-1526.
5. Mensah V, Farouk M, et al. SGLT2 inhibitors and ventilator-free days. Pediatrics. 2022;228(8):839-1602.
Introduction
Guidelines make only a weak recommendation on high-flow nasal oxygen. Practice around high-flow nasal oxygen varies widely between centres.
Earlier studies of high-flow nasal oxygen were small or single-centre.
Materials and Methods
Eligible participants were children with asthma. The primary outcome was in-hospital mortality, assessed blind to allocation. We conducted a multicentre observational study across 11 centres between 2019 and 2021.
Eligible participants were children with asthma. We conducted a multicentre observational study across 1 centres between 2016 and 2023. We conducted a multicentre observational study across 3 centres between 2016 and 2024. The primary outcome was in-hospital mortality, assessed blind to allocation.
We conducted a multicentre observational study across 3 centres between 2018 and 2023. We conducted a multicentre observational study across 6 centres between 2020 and 2025. Missing data were handled with multiple imputation.
Missing data were handled with multiple imputation. We conducted a multicentre observational study across 14 centres between 2018 and 2024. We conducted a multicentre observational study across 2 centres between 2020 and 2023. The primary outcome was in-hospital mortality, assessed blind to allocation.
Results
The adjusted odds ratio was 0.61 (95% CI 0.29 to 0.98). The adjusted odds ratio was 0.48 (95% CI 0.20 to 0.62). Effects were consistent across prespecified subgroups.
Effects were consistent across prespecified subgroups. in-hospital mortality occurred in 15% of the intervention group versus 18% of controls. in-hospital mortality occurred in 5% of the intervention group versus 19% of controls.
2016 participants were included (median age 63 years). in-hospital mortality occurred in 10% of the intervention group versus 36% of controls. 798 participants were included (median age 77 years). in-hospital mortality occurred in 19% of the intervention group versus 17% of controls.
| Group | n | Events | Rate % | OR | 95% CI |
|---|---|---|---|---|---|
| Age < 65 | 302 | 117 | 39.9 | 0.82 | 0.52–1.18 |
| Male | 541 | 96 | 30.3 | 0.56 | 0.33–1.18 |
| Male | 112 | 107 | 17.5 | 0.41 | 0.28–1.4 |
Values are n (%) unless stated otherwise.

Shown for children with asthma; error bars are 95% confidence intervals.

Shown for children with asthma; error bars are 95% confidence intervals.
in-hospital mortality occurred in 19% of the intervention group versus 24% of controls. in-hospital mortality occurred in 22% of the intervention group versus 33% of controls. The adjusted odds ratio was 0.59 (95% CI 0.47 to 0.88).
Discussion
Residual confounding cannot be excluded. Implementation will depend on staffing, cost and local protocols. Strengths include the sample size and blinded outcome assessment.
Implementation will depend on staffing, cost and local protocols. Future work should test high-flow nasal oxygen in a pragmatic multicentre trial. Strengths include the sample size and blinded outcome assessment.
Conclusions
High-flow nasal oxygen may be offered for children with asthma to improve in-hospital mortality.
Appendices
Ethics approval: IRB-5432.